
ORIGINAL RESEARCH

THE EFFECT OF ACETYLSALICYLIC ACID ON ANGIOGENESIS *IN VITRO*

Klara Pizova^{1,2}, Adela Hanakova^{1,2}, Outi Huttala³, Jertta-Riina Sarkanen³,
Tuula Heinonen³, Dagmar Jírová⁴, Kristina Kejlova⁴, Hana Kolarova^{1,2}

¹Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University,
Olomouc, Czech Republic

²Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky
University, Olomouc, Czech Republic

³Finnish Center for Alternative Methods, Medical School, University of Tampere, Tampere, Finland

⁴National Institute of Public Health, Prague, Czech Republic

Abstract

Angiogenesis, the formation of new blood vessels, is an essential aspect of, among others, embryonic development, wound healing and the female reproductive cycle. It is also necessary for the expansion of tumour masses beyond a minute volume. Acetylsalicylic acid (ASA) is a non-steroidal anti-inflammatory drug with additional antitumour activity. We tested ASA for its ability to inhibit angiogenesis in a simplified angiogenesis model, hASC+HUVEC co cultured in vitro, using immunocytochemical staining with fluorescence-marked antibodies and observation of tubule-like structures and their branching under a fluorescence microscope. We confirmed that ASA is an efficient and useful angiogenesis inhibitor and deserves further attention. We intend using the designed angiogenesis model and the methods described for observing changes in angiogenesis after anti tumour photodynamic therapy (PDT), and also for enhancing PDT efficiency by addition of angiogenesis inhibitors.

Keywords

angiogenesis, acetylsalicylic acid, hASC+HUVEC co-culture

Introduction

Angiogenesis is the formation of new blood vessels. It is a multistep process, regulated by an interplay of pro- and anti-angiogenic factors involving endothelial cell proliferation, migration, differentiation, and tubule formation, as well as stabilization of newly-formed blood vessels. Angiogenesis is a critical aspect of essential physiological processes such as in embryonic development, wound healing, and the female reproductive cycle, as well as in pathological processes such as in tumor development, macular degeneration,

rheumatoid arthritis, ischemic diseases, endometriosis and psoriasis [1-4].

Investigation of angiogenic mechanisms require assays that simulate the key steps in angiogenesis and provide tools for assessing the efficacy of therapeutic agents that either upregulate or down-regulate specific angiogenic mechanisms. The evaluation of factors that affect angiogenesis would optimally be studied *in vivo* due to complex interactions during angiogenesis. Despite the advantage of providing more information on complex cellular and molecular interactions compared to *in vitro* models, animal models have

several disadvantages (such as variability, animal-specificity, and ethics). For this reason, human cell based assays *in vitro* would have more validity and extrapolation to humans. Although tubule formation *in vitro* does not cover the whole angiogenesis process, it effectively imitates the key steps (migration and differentiation of endothelial cells). Moreover, *in vitro* angiogenesis assays provide an opportunity to investigate angiogenic mechanisms and assess the efficacy of therapeutic agents with speed and simplicity that cannot be achieved using *in vivo* assays. The search for anti-angiogenic agents (mainly for the treatment of cancer) is particularly important at the current time. [1,3,4,5]

Acetylsalicylic acid (ASA) is one of the non-steroidal anti-inflammatory drugs (NSAIDs), widely used for the treatment of acute and chronic pain and inflammation. Studies [6-14] have shown that NSAIDs can reduce the risk of many types of cancer suggesting that these drugs may possess tumour-suppressive activity. Recent advances made in a number of laboratories have provided strong evidence that the anti-tumour activity of NSAIDs is associated with suppression of tumour angiogenesis. The formation of a vascular network in the tumour stroma (tumour angiogenesis) plays a critical role in tumour progression and metastasis formation. The absence or destruction of tumour-associated vasculature leads to tumour death via anoxia and lack of nutrients. Hence, inhibition of angiogenesis by NSAIDs may be an important way of combating cancer. [3,15,16]



Experiments

Our aim was to test ASA for its ability to inhibit angiogenesis on a simplified and improved angiogenesis model *in vitro* (designed by the scientific group from FICAM).

For our experiments, we used cell lines hASC (human adipose stem cells, 22 000 cells/well) and HUVEC (human umbilical vein endothelial cells, 4 000 cells/well) and treated hASC+HUVEC co-culture by acetylsalicylic acid (ASA) in a concentration 2, 1, 0.5, 0.25 and 0.125 mmol/l. Further, we stained samples with a staining cocktail of 2 primary antibodies (anti-von Willebrand factor, anti-Collagen) and subsequently by a staining cocktail of 2 secondary antibody (anti-rabbit IgG TRITC, anti-mouse IgG FITC). We then observed tubule-like structures and their branching under a fluorescence microscope Nikon Eclipse Ti and software NIS-Elements F 3.0.

Fig 1B shows many tubules in the positive control, grown in the presence of growth factors and no tubules in the negative control grown in simple media without growth factors (Fig 1A). In the sample treated with the highest used ASA concentration, 2mM, fewer vessels can be seen (Fig 1F) whereas the sample with the lowest used ASA concentration, 0.125mM, (Fig 1C) looks similar to the positive control. Thus, 2 mM ASA appears to be effective but 0.125mM was not sufficient to inhibit angiogenesis.

We confirmed our prediction that ASA (mainly in a concentration of 2 mmol/l) is an efficient angiogenesis inhibitor and deserves our further attention.






Fig. 1: Formation of tubule-like structures by hASC+HUVEC co-culture incubated in (A) simple medium without growth factors (B) stimulation medium with growth factors VEGF and FGF β (C) stimulation medium with growth factors and 0.125mM ASA (D) stimulation medium with growth factors and 0.25mM ASA (E) stimulation medium with growth factors and 0.5mM ASA (F) stimulation medium with growth factors and 1mM ASA (G) stimulation medium with growth factors and 2mM ASA. Magnitude 100x.

Conclusion

Our group focus on testing photoactive substances called photosensitizers *in vitro* which in combination with visible light (photodynamic therapy - PDT) destroy cancer cells [17-27]. Search for and development of more efficient antitumour therapies is of paramount importance and PDT in particular is attracting much attention owing to its exceptional selectivity and specificity. Angiogenesis plays a critical role in tumour progression. Moreover, it is known that PDT combined with some photosensitizers (such as Photofrin, Verteporfin, telaporfin, 5-aminolevulinic acid, NPe6, phthalocyanines and others) induces, besides direct cytotoxic effects, destruction of tumour-associated vasculature which can lead to tumour death via lack of oxygen and nutrients [28, 29].

It would be very interesting and useful to combine the experiences of both scientific groups and use the designed angiogenesis model for observing changes in angiogenesis, a major factor in cancer development, after PDT, and for enhancing PDT efficiency by addition of angiogenesis inhibitors. In the future, PDT

in combination with antiangiogenic agents such as ASA will offer promising alternatives to currently used treatment approaches for malignant tumours, namely, radiotherapy, chemotherapy and surgery.

Acknowledgements

Work was supported by grants CZ.1.05/2.1.00/01.0030 and CZ.1.07/2.4.00/17.0015, and NT 14375-3/2013 from the Ministry of Health.

References

- [1] Auerbach, R., Lewis, R., Shimmers, B., Kubai, L., Akhtar, N. *Angiogenesis assays: a critical overview*. Clin Chem, 2003, vol. 49, no. 1, p. 32-40.
- [2] Friis, T., Kjaer, Sørensen, B., Engel, A. M., Rygaard, J., Houen, G. *A quantitative ELISA-based co-culture angiogenesis and cell proliferation assay*. APMIS, 2003, vol. 111, no. 6, p. 658-668.
- [3] Norrby, K. *In vivo models of angiogenesis*. J Cell Mol Med, 2006, vol. 10, no. 3, p. 588-612.

- [4] Sarkanen, J. R., Mannerström, M., Vuorenperä, H., Uotila, J., Ylikomi, T., Heinonen, T. *Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators*. *Front Pharmacol*, 2011, vol. 147, no. 1. doi: 10.3389/fphar.2010.00147.
- [5] Donovan, D., Brown, N. J., Bishop, E. T., Lewis, C. E. *Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo*. *Angiogenesis*, 2001, vol. 4, no. 2, p. 113-121.
- [6] García-Rodríguez, L. A., Huerta-Alvarez, C. *Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs*. *Epidemiology*, 2001, vol. 12, no. 1, p. 88-93.
- [7] Flossmann, E., Rothwell, P. M. *British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies*. *Lancet*, 2007, vol. 369, no. 9573, p. 1603-1613.
- [8] Rothwell, P. M., Wilson, M., Elwin, C. E., Norrving, B., Algra, A., Warlow, C. P., Meade, T. W. *Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials*. *Lancet*, 2010, vol. 376, no. 9754, p. 1741-1750.
- [9] Benamouzig, R., Uzzan, B., Martin, A., Deyra, J., Little, J., Girard, B., Chaussade, S. *APACC Study Group. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention*. *Gut*, 2010, vol. 59, no. 5, p. 622-629.
- [10] Benamouzig, R., Uzzan, B., Deyra, J., Martin, A., Girard, B., Little, J., Chaussade, S. *Association pour la Prévention par l'Aspirine du Cancer Colorectal Study Group (APACC). Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial*. *Gut*, 2012, vol. 61, no. 2, p. 255-261.
- [11] Zubiaurre, L., Bujanda Fernández de Pierola, L. *Aspirin in the prevention of colorectal cancer*. *Gastroenterol Hepatol*, 2011, vol. 34, no. 5, p. 337-345.
- [12] Dhillon, P. K., Kenfield, S. A., Stampfer, M. J., Giovannucci, E. L., Chan, J. M. *Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort*. *Cancer Prev Res (Phila)*, 2012, vol. 5, no. 10, p. 1223-1228.
- [13] Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., Mehta, Z. *Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials*. *Lancet*, 2012, vol. 379, no. 9826, p. 1591-1601.
- [14] Zhang, X., Wang, Z., Wang, Z., Zhang, Y., Jia, Q., Wu, L., Zhang, W. *Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model*. *Oncol Rep*, 2013, vol. 29, no. 5, p. 1907-1913.
- [15] Dermond, O., Rüegg, C. *Inhibition of tumor angiogenesis by non-steroidal anti-inflammatory drugs: emerging mechanisms and therapeutic perspectives*. *Drug Resist Updat*, 2001, vol. 4, no. 5, p. 314-321.
- [16] Monnier, Y., Zaric, J., Rüegg, C. *Inhibition of angiogenesis by non-steroidal anti-inflammatory drugs: from the bench to the bedside and back*. *Curr Drug Targets Inflamm Allergy*, 2005, vol. 4, no. 1, p. 31-38.
- [17] Kolarova, H., Nevrelva, P., Bajgar, R., Jirova, D., Kejlova, K., Strnad, M. *In vitro photodynamic therapy on melanoma cell lines with phthalocyanine*. *Toxicol In Vitro*, 2007, vol. 21, no. 2, p. 249-253.
- [18] Kolarova, H., Bajgar, R., Tomankova, K., Nevrelva, P., Mosinger, J. *Comparison of sensitizers by detecting reactive oxygen species after photodynamic reaction in vitro*. *Toxicol In Vitro*, 2007, vol. 21, no. 7, p. 1287-1291.
- [19] Kolarova, H., Lenobel, R., Kolar, P., Strnad, M. *Sensitivity of different cell lines to phototoxic effect of disulfonated chloroaluminium phthalocyanine*. *Toxicol In Vitro*, 2007, vol. 21, no. 7, p. 1304-1306.
- [20] Kolarova, H., Bajgar, R., Tomankova, K., Krestyn, E., Dolezal, L., Halek, J. *In vitro study of reactive oxygen species production during photodynamic therapy in ultrasound-pretreated cancer cells*. *Physiol Res*, 2007, vol. 56 (Suppl 1), p. S27-32.
- [21] Kolarova, H., Nevrelva, P., Tomankova, K., Kolar, P., Bajgar, R., Mosinger, J. *Production of reactive oxygen species after photodynamic therapy by porphyrin sensitizers*. *Gen Physiol Biophys*, 2008, vol. 27, no. 2, p. 101-105.
- [22] Tomankova, K., Kolarova, H., Bajgar, R. *Study of photodynamic and sonodynamic effect on A549 cell line by AFM and measurement of ROS production*. *Phys Stat Sol (a)*, 2008, vol. 205, no. 6, p. 1472-1477.
- [23] Kolarova, H., Tomankova, K., Bajgar, R., Kolar, P., Kubinek, R. *Photodynamic and sonodynamic treatment by phthalocyanine on cancer cell lines*. *Ultrasound Med Biol*, 2009, vol. 35, no. 8, p. 1397-1404.
- [24] Krestyn, E., Kolarova, H., Bajgar, R., Tomankova, K. *Photodynamic properties of ZnTPPS₄, ClAlPcS₂ and ALA in human melanoma G361 cells*. *Toxicol In Vitro*, 2010, vol. 24, no. 1, p. 286-291.
- [25] Binder, S., Kolarova, H., Tomankova, K., Bajgar, R., Daskova, A., Mosinger, J. *Phototoxic effect of TPPS₄ and MgTPPS₄ on DNA fragmentation of HeLa cells*. *Toxicol In Vitro*, 2011, vol. 25, no. 6, p. 1169-1172.
- [26] Hanakova, A., Bogdanova, K., Tomankova, K., Binder, S., Bajgar, R., Langova, K., Kolar, M., Mosinger, J., Kolarova, H. *Study of photodynamic effects on NIH 3T3 cell line and bacteria*. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2012, vol. 156, doi: 10.5507/bp.2012.057.
- [27] Hanakova, A., Bogdanova, K., Tomankova, K., Pizova, K., Malohlava, J., Binder, S., Bajgar, R., Langova, K., Kolar, M., Mosinger, J., Kolarova, H. *The application of antimicrobial photodynamic therapy on S. aureus and E. coli using porphyrin photosensitizers bound to cyclodextrin*. *Microbiol Res*, 2014, vol. 169, no. 2-3, p. 163-170.
- [28] Kudinova, N. V., Berezov, T. T. *Photodynamic Therapy of Cancer: Search For Ideal Photosensitizer*. *Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry*, 2010, vol. 4, no. 1, pp. 95-103.
- [29] Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., Korbelik, M., Moan, J., Mroz, P., Nowis, D., Piette, J., Wilson, B. C., Golab, J. *Photodynamic therapy of cancer: an update*. *CA Cancer J Clin*, 2011, vol. 61, no. 4, p. 250-281.

Mgr. Klára Pířová

Department of Medical Biophysics
Faculty of Medicine and Dentistry
Palacky University in Olomouc
Hněvotínská 3
775 15 Olomouc
Czech Republic

E-mail: pizova.klara@seznam.cz
tel.: +420 585 632 110